MyronSCzuczmanMD
Internal Medicine • Buffalo, NYHematology/Oncology
Professor of Medicine, SUNY Buffalo
Are you Dr. Czuczman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 85 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Elm And Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-3894- Is this information wrong?
Summary
- Dr. Myron Czuczman, MD is a board certified internist in Buffalo, New York. He is currently licensed to practice medicine in New York. He is affiliated with KALEIDA Health and is a Professor of Medicine at SUNY Buffalo.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1992
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1988
Pennsylvania State University College of MedicineClass of 1985
Certifications & Licensure
NY State Medical License 1987 - 2026- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Buffalo Spree Magazine Castle Connolly, 2008, 2010-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
Clinical Trials
- 506U78 in Treating Patients With Lymphoma Start of enrollment: 2000 May 01
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma Start of enrollment: 2001 Mar 01
- Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma Start of enrollment: 2005 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsDurvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini...> ;Cancer Reports. 2023 Jan 1
- 103 citationsROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belad...> ;Journal of Clinical Oncology. 2021 Feb 23
- 8 citationsBiomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.Aliyah R. Sohani, Matthew J. Maurer, Sharmila Giri, Brandelyn Pitcher, Amy Chadburn, Jonathan W. Said, Nancy L. Bartlett, Myron S. Czuczman, Peter Martin, Sin-Ho Jung,...> ;The American Journal of Surgical Pathology. 2021 Mar 1
- Join now to see all
Press Mentions
Citius Enters Partnership for Phase I/Ib Solid Tumour Treatment TrialSeptember 23rd, 2022- Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)October 13th, 2021
- Citius Pharmaceuticals : Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-cell Lymphoma and Other Cancer Indications (Form 8-K)September 7th, 2021
- Join now to see all
Hospital Affiliations
KALEIDA HealthBuffalo, New York
